All Pharma News
Verve Halts Trial for Lead Gene Editing Program Due to Safety Concerns

Verve Halts Trial for Lead Gene Editing Program Due to Safety Concerns
Tristan Manalac BIOSPACE
03 Apr 2024
Share Share
Verve Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

Verve Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
PRESS RELEASE
27 Feb 2024
Share Share
Verve to Participate in Guggenheim Healthcare Talks 6th Annual Conference

Verve to Participate in Guggenheim Healthcare Talks 6th Annual Conference
PRESS RELEASE
01 Feb 2024
Share Share
Verve raises $148M via public stock offering

Verve raises $148M via public stock offering
Katherine Lewin ENDPTS
29 Nov 2023
Share Share
Verve Therapeutics Announces Proposed Public Offering of Common Stock

Verve Therapeutics Announces Proposed Public Offering of Common Stock
PRESS RELEASE
28 Nov 2023
Share Share
Verve Therapeutics Announces Pricing of Public Offering of Common Stock

Verve Therapeutics Announces Pricing of Public Offering of Common Stock
PRESS RELEASE
28 Nov 2023
Share Share
Verve shows base editing works in humans—and sees stock sink

Verve shows base editing works in humans—and sees stock sink
FIERCE BIOTECH
13 Nov 2023
Share Share
Verve Therapeutics Announces Interim Data for VERVE-101

Verve Therapeutics Announces Interim Data for VERVE-101
PRESS RELEASE
12 Nov 2023
Share Share
Verve Therapeutics Reports Third Quarter 2023 Financial Results

Verve Therapeutics Reports Third Quarter 2023 Financial Results
GLOBENEWSWIRE
09 Nov 2023
Share Share
Verve Therapeutics Reports Third Quarter 2023 Financial Results

Verve Therapeutics Reports Third Quarter 2023 Financial Results
PRESS RELEASE
07 Nov 2023
Share Share